Antibe Therapeutics completes pre-clinical program for its lead product ATB-346
Published on March 17, 2014 at 8:23 AM
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV: ATE) is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.
ATB-346 targets the global need for a GI-safe anti-inflammatory painkiller, a growing market that currently generates annual sales of over $12 billion. Said Chief Scientific Officer Dr. John Wallace, "We are delighted that the planned pre-clinical studies have been finished, and that these studies confirm and expand upon the extensive academic work already conducted on ATB-346. We are grateful to our partners and service providers for their assistance, which has enabled us to conduct these studies on schedule."
CEO Dan Legault added, "It is a significant milestone for Antibe to have completed its planned pre-clinical work on ATB-346. We look forward to sharing additional progress with Antibe's stakeholders as we proceed with an application to Health Canada for permission to initiate the first human trials later this year."